Neurodegenerative disease-focused VectorY nabs $138M to bring ALS vectorized antibody to clinic
Seeded by European VC firm Forbion in 2021, vectorized antibody startup VectorY has another $138 million to work with in a Series A co-led once again by Forbion’s Growth Opportunities Fund, with the company calling it one of the largest private biotech financings in Europe this year.
VectorY is first going after amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, in its mission to target neurodegenerative diseases. The Series A will go toward the clinical development of its lead vectorized antibody program, VTx-002, which targets TDP-43, the major pathological protein in sporadic ALS, according to the NIH.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.